Boehringer Ingelheim and Lilly launch new diabetes survey

Boehringer Ingelheim and Lilly have allied with the International Diabetes Federation to launch a new survey assessing the impact of early conversations between physicians and type 2 diabetes patients.

This will be the largest multinational survey ever conducted on this subject and will include more than 10,000 people with type 2 diabetes and in excess of 6,500 treating physicians across 26 countries worldwide.

It will provide in-depth insights into early conversations at diagnosis and when additional therapies may be required beyond the first medication, as well as how these encounters are linked to an individual's wellbeing and other self-reported outcomes.

Anne Belton, vice-president at the International Diabetes Federation, said: "This new survey will provide valuable insights into these important early conversations and will help aid the development of solutions for physicians and people with type 2 diabetes."

Boehringer Ingelheim and Lilly have been collaborating in the field of diabetes for several years and are responsible for developing Trajenta, a clinically proven treatment for type 2 diabetes.